OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
TLX597-Tx is a PSMA[1]-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. OPTIMAL-PSMA[2] initial dosimetry data demonstrate low salivary gland and kidney...
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces an educational webinar exploring the evolution of PSMA[1]-targeted radionuclide therapy and Telix's...
Co-PSMA data published in the European Urology journal
SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with...
Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
HIGHLIGHTS Oral presentation on key results from the Co-PSMA (NCT06907641)[ 1] Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent's Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the...